Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AZTR

Azitra Inc

Oct 27 • 04:00PM ET

0.5460

-0.0239 -4.19 %

Healthcare • Biotechnology • USA • AMEX

Peers: ANAB FATE VYGR AKTX TVRD ARWR ORMP PULM ARMP BCRX

Index	-	P/E	-	EPS (ttm)	-5.98	Insider Own	0.23%	Shs Outstand	5.41M	Perf Week	-20.84%
Market Cap	2.95M	Forward P/E	-	EPS next Y	-3.21	Insider Trans	0.00%	Shs Float	5.39M	Perf Month	-22.00%
Enterprise Value	2.48M	PEG	-	EPS next Q	-0.76	Inst Own	8.36%	Short Float	1.38%	Perf Quarter	-56.60%
Income	-9.36M	P/S	-	EPS this Y	75.10%	Inst Trans	-0.70%	Short Ratio	0.02	Perf Half Y	-72.41%
Sales	0.00M	P/B	0.66	EPS next Y	18.32%	ROA	-238.82%	Short Interest	0.07M	Perf YTD	-80.73%
Book/sh	0.83	P/C	2.81	EPS next 5Y	40.83%	ROE	-473.31%	52W High	4.33 -87.39%	Perf Year	-85.69%
Cash/sh	0.19	P/FCF	-	EPS past 3/5Y	56.64% -	ROIC	-373.88%	52W Low	0.50 8.14%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-59.15% -	Gross Margin	-	Volatility	16.46% 12.13%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	95.01%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.24	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	31.29	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.24	EPS Q/Q	93.53%	SMA20	-19.78%	Beta	-1.69	Target Price	4.00
Payout	-	Debt/Eq	0.26	Sales Q/Q	-100.00%	SMA50	-29.66%	Rel Volume	0.62	Prev Close	0.57
Employees	12	LT Debt/Eq	0.12	Earnings	Aug 11 AMC	SMA200	-66.23%	Avg Volume	4.11M	Price	0.55
IPO	Jun 16, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	14.29% -	Trades		Volume	2,544,797	Change	-4.19%

Oct-20-25 08:02AM	Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris (PR Newswire)
Oct-03-25 04:45PM	Azitra Receives Notice of Non-Compliance from NYSE American (PR Newswire) +7.39%
Sep-04-25 08:10AM	Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire) -9.79%
Aug-27-25 04:44PM	Why Is Azitra (AZTR) Stock Soaring Today (GuruFocus.com) +35.88%
08:10AM	Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash (PR Newswire)
05:00PM	Loading…
Aug-11-25 05:00PM	Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates (PR Newswire) -7.61%
04:15PM	Azitra, Inc. Announces Reverse Stock Split (PR Newswire)
Jun-17-25 08:02AM	Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome (PR Newswire)
Jun-10-25 08:33AM	Azitra, Inc. Announces Presentation at the 2025 BIO International Convention (PR Newswire)
May-28-25 08:33AM	Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash (PR Newswire)
May-14-25 04:05PM	Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash (PR Newswire)
May-13-25 05:06PM	Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates (PR Newswire)
Apr-25-25 08:33AM	Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025 (PR Newswire)
Apr-24-25 04:05PM	Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline (PR Newswire)
Mar-12-25 08:33AM	Azitra to Present at Microbiome Times Partnering Forum (PR Newswire)
08:30AM	Loading…
Feb-24-25 08:30AM	Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates (PR Newswire)
Feb-04-25 02:20PM	Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock (PR Newswire) +16.34%
Feb-03-25 09:05AM	Azitra, Inc. to Present at the BIO CEO & Investor Conference (PR Newswire) +15.08%
Jan-27-25 04:05PM	Azitra, Inc. to Present at The Microcap Conference (PR Newswire) -6.64% +20.35%
Jan-15-25 08:30AM	Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock (PR Newswire) -39.03%
Jan-14-25 04:05PM	Azitra Announces Proposed Public Offering of Common Stock (PR Newswire) -26.75%
Nov-12-24 05:05PM	Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates (PR Newswire)
Oct-29-24 09:00AM	Azitra to Present at BIO-Europe 2024 (Business Wire)
Oct-11-24 09:00AM	Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Sep-24-24 08:00AM	Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress (Business Wire)
Sep-18-24 09:00AM	Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors (Business Wire) +5.82%
Sep-06-24 04:30PM	Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-28-24 08:30AM	Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome (Business Wire)
Aug-22-24 09:00AM	Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors (Business Wire) +11.14%
Aug-20-24 04:15PM	Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome (Business Wire) +5.98%
06:23PM	Loading…
Aug-12-24 06:23PM	Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates (Business Wire)
Jul-25-24 05:57PM	CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering (Business Wire) -9.65%
Jul-23-24 09:20PM	Azitra, Inc. Announces Pricing of $10.0 Million Public Offering (Business Wire) +206.79% -76.46%
08:00AM	Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents (Business Wire)
Jun-27-24 04:05PM	Azitra, Inc. Announces Reverse Stock Split (Business Wire) +12.72% -30.15%
May-31-24 08:00AM	Azitra, Inc. Announces Presentation at the 2024 BIO International Convention (Business Wire)
May-17-24 08:00AM	Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting (Business Wire) -8.22%
May-10-24 08:00AM	Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting (Business Wire) -13.08%
May-09-24 05:00PM	Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates (Business Wire)
Apr-22-24 04:30PM	Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting (Business Wire) +18.77%
Apr-18-24 04:15PM	Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024 (Business Wire) -5.10%
Mar-15-24 04:15PM	Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates (Business Wire)
Feb-16-24 04:05PM	Azitra, Inc. Announces Closing of Public Offering (Business Wire) +6.01% +5.79%
Feb-13-24 10:09PM	Azitra, Inc. Announces Pricing of Public Offering (Business Wire) -24.33% -73.91%
Jan-16-24 09:00AM	Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US (Business Wire) +32.50%
Jan-03-24 09:00AM	Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference (Business Wire) +11.42%
Nov-14-23 04:30PM	Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates (Business Wire)
Oct-16-23 08:00AM	Azitra to Present at the ThinkEquity Conference (Business Wire) +7.59%
Aug-29-23 08:00AM	Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 04:05PM	Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates (PR Newswire) -6.52%
Jul-19-23 04:05PM	Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors (PR Newswire)
Jul-11-23 04:05PM	Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer (PR Newswire)
Jun-21-23 06:46PM	Azitra, Inc. Announces Closing of Initial Public Offering (PR Newswire) +9.62%
Jun-15-23 07:04PM	Azitra, Inc. Announces Pricing of Initial Public Offering (PR Newswire)

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZTR

Azitra Inc

Upgrade your FINVIZ experience